PAVmed (PAVM) Q1 2025 Earnings – Full Coverage

Описание: *PAVmed (PAVM) Q1 2025 Earnings – Full Coverage*

*Key Highlights:*
*Financials* – Q1 2025 operating expenses $5.4M, non-GAAP loss $0.91M, GAAP net income $18.6M ($1.28/share, driven by $21M Lucid share gain); cash $2.8M, reduced debt by $25M via Series C preferred exchange.
*Operations* – Lucid Diagnostics revenue $0.8M, 3,034 EsoGuard tests; Verus Health restarted implantable monitor development; PMX incubator advanced PortIO with strategic talks; 29% Lucid ownership.
*Strategy* – CEO Lishan Aklog emphasized diversified life sciences model, Lucid’s Medicare coverage pursuit, Verus’ OSU partnership, and biopharma expansion; targets independent subsidiary financing and strategic partnerships.
*Outlook* – Expects Lucid Medicare coverage soon, Verus FDA filing in H1 2026, 1,000+ OSU patients in 2025, and PortIO strategic deal; projects biopharma asset acquisition to leverage clinical research capabilities.

*Timestamps:*
[00:00] – Opening Remarks and Introduction
[00:39] – Safe Harbor and Overview (Matt Reilly)
[02:12] – CEO Strategic Update (Lishan Aklog)
[04:49] – Lucid Diagnostics Progress
[06:16] – Verus Health and PMX Incubator Updates
[08:14] – Financial Results (Dennis McGrath)
[16:40] – Q&A Session Begins
[16:40] – Verus Pilot Program Feedback (Jeremy Perlman)
[20:56] – Verus Platform Exclusivity
[22:56] – Biopharma Expansion Strategy
[26:35] – Capital Raising Amid Market Volatility (Edward Yu)

*Keywords:* PAVmed, Q1 2025 earnings, PAVM stock, Lucid Diagnostics, Verus Health, PortIO, biopharma, EsoGuard, Medicare coverage, shared services, strategic partnerships

*Buy, Hold, or Sell?*
PAVmed (PAVM) is a **BUY**. Strengthened balance sheet, Lucid’s near-term milestones, and biopharma expansion potential position the company for significant shareholder value creation.

*Max Position* – Allocate *3-5%* in a diversified portfolio.

*Comment below with your thoughts! Subscribe for more updates!*
*Full Details:* [PAVmed Investor Relations](https://www.pavmed.com/investors)

*Disclaimer:* This video includes segments from the earnings call by PAVmed, used solely for educational and informational purposes under fair use (Section 107, US Copyright Act). No affiliation or endorsement by PAVmed is implied. All rights to the original content remain with the company. For the official call, visit [https://www.pavmed.com/investors](https://www.pavmed.com/investors). For inquiries or requests for removal, please contact us at [email protected].